Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Purchases 7,851 Shares

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt bought 7,851 shares of the firm’s stock in a transaction that occurred on Thursday, July 2nd. The stock was bought at an average cost of $3.54 per share, for a total transaction of $27,792.54. Following the completion of the acquisition, the insider owned 90,407 shares in the company, valued at $320,040.78. This trade represents a 9.51% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.51, for a total value of $31,667.22.
• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Down 6.9%

SHPH stock opened at $3.26 on Wednesday. Shuttle Pharmaceuticals Holdings, Inc. has a twelve month low of $2.90 and a twelve month high of $55.90. The stock has a market cap of $2.09 million, a P/E ratio of -0.07 and a beta of 0.29. The business’s 50-day moving average price is $5.43 and its 200-day moving average price is $10.37.

Analysts Set New Price Targets

Several brokerages have weighed in on SHPH. Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wall Street Zen upgraded shares of Shuttle Pharmaceuticals to a “sell” rating in a research report on Saturday. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Trading of Shuttle Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at approximately $26,000. Boothbay Fund Management LLC bought a new position in Shuttle Pharmaceuticals in the 4th quarter worth approximately $37,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals during the 4th quarter valued at approximately $124,000. Finally, Connective Capital Management LLC bought a new stake in shares of Shuttle Pharmaceuticals during the third quarter valued at approximately $357,000. Hedge funds and other institutional investors own 4.58% of the company’s stock.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .